Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

Blood (2024) 144 (Supplement 1): 84.

https://doi.org/10.1182/blood-2024-201972

Published: 2024

Journal Articles

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Blood (2024) 144 (Supplement 1): 859.

https://doi.org/10.1182/blood-2024-200604

Published: 2024

Journal Articles

Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma

Blood (2024) 144 (Supplement 1): 1963.

https://doi.org/10.1182/blood-2024-205230

Published: 2024

Journal Articles

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Blood (2023) 142 (Supplement 1): 1897.

https://doi.org/10.1182/blood-2023-173707

Published: 2023

Journal Articles

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Blood (2023) 142 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2023-189169

Published: 2023

Journal Articles

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Blood (2023) 142 (Supplement 1): 782.

https://doi.org/10.1182/blood-2023-178835

Published: 2023

Journal Articles

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Blood (2022) 140 (Supplement 1): 1836–1838.

https://doi.org/10.1182/blood-2022-156309

Published: 2022

Journal Articles

Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network

Blood (2021) 138 (Supplement 1): 3792.

https://doi.org/10.1182/blood-2021-145289

Published: 2021

Journal Articles

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

Blood (2021) 138 (Supplement 1): 486.

https://doi.org/10.1182/blood-2021-147323

Published: 2021

Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Nadine Kutsch, MD, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Clemens-Martin Wendtner, Michael J. Eckart, Stephan Stilgenbauer, Xi Huang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD

Blood (2019) 134 (Supplement_1): 3047.

https://doi.org/10.1182/blood-2019-131025

Published: 2019

Journal Articles

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Christian Schmidt, MD, Anna-Katharina Zoellner, Vindi Jurinovic, Martin Sökler, MD, Roswitha Forstpointner, Sascha Haubner, MD, Christian Buske, MD, Andreas Viardot, MD, Ulrich Keller, Christiane Pott, Ullrich Graeven, MD, Reinhard Marks, Mathias Hänel, MD, Ruediger Liersch, Jan Dürig, Eva Hoster, Michael Unterhalt, Wolfgang Hiddemann

Blood (2018) 132 (Supplement 1): 448.

https://doi.org/10.1182/blood-2018-99-111692

Published: 2018

Journal Articles

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Blood (2018) 132 (Supplement 1): 253.

https://doi.org/10.1182/blood-2018-99-111203

Published: 2018

Journal Articles

Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma

Blood (2018) 132 (Supplement 1): 254.

https://doi.org/10.1182/blood-2018-99-119762

Published: 2018

Journal Articles

Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial

Blood (2016) 128 (22): 3373.

https://doi.org/10.1182/blood.V128.22.3373.3373

Published: 2016

Journal Articles

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Jan Braess, MD, Karl-Anton Kreuzer, Karsten Spiekermann, PhD, Hans Walter Lindemann, MD, Eva Lengfelder, MD, Ullrich Graeven, Peter Staib, MD, Wolf-Dieter Ludwig, Harald Biersack, Yon-Dschun Ko, MD, Michael J. Uppenkamp, Stefan Korsten, Maike De Wit, Rudolf Peceny, MD, Tobias Gaska, MD, Xaver Schiel, Dirk M Behringer, MD, Michael G. Kiehl, MD, PhD, Bettina Zinngrebe, Gerald Meckenstock, Eva Roemer, Dirk Medgenberg, Ernst Spaeth-Schwalbe, MD, Birgit Braess, MD, Gero Massenkeil, MD, Heidrun Hindahl, Guido Trenn, Rainer Schwerdtfeger, MD, Susanne Amler, MSc, Cristina Sauerland, MSc, Andreas Faldum, MD, Michael Unterhalt, M.D. Ph.D., Stefan K. Bohlander, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Christian Buske, MD, Michael Fiegl, MD, Marion Subklewe, MD, Anja Baumgartner, PhD, Bernhard J. Woermann, MD, Dietrich Beelen, MD, Wolfgang Hiddemann, MD

Blood (2013) 122 (21): 619.

https://doi.org/10.1182/blood.V122.21.619.619

Published: 2013

Journal Articles

Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma

Boris Böll, Henning Bredenfeld, Helen Görgen, Teresa Halbsguth, Hans T. Eich, Martin Soekler, Jana Markova, Ulrich Keller, Ullrich Graeven, Stephan Kremers, Michael Geissler, Guido Trenn, Michael Fuchs, Bastian von Tresckow, Dennis A. Eichenauer, Peter Borchmann, Andreas Engert

Blood (2011) 118 (24): 6292–6298.

https://doi.org/10.1182/blood-2011-07-368167

Published: 2011

Journal Articles

Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial

Blood (2011) 118 (21): 332.

https://doi.org/10.1182/blood.V118.21.332.332

Published: 2011

Journal Articles

Front - Line Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves the Time to Treatment Failure and Overall Survival in Elderly Patients with Advanced Stage Follicular Lymphoma - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Christian Buske, MD, Michael Kneba, MD, PhD, Eva Lengfelder, MD, Michael Pfreundschuh, MD, Wolf-Dieter Ludwig, MD, Ullrich Graeven, MD, Michael Hallek, MD, Martin Dreyling, MD, Michael Unterhalt, MD, Wolfgang Hiddemann, MD, PhD

Blood (2006) 108 (11): 482.

https://doi.org/10.1182/blood.V108.11.482.482

Published: 2006

Journal Articles

Vascular Endothelial Growth Factor, a Possible Paracrine Growth Factor in Human Acute Myeloid Leukemia

Walter Fiedler, Ullrich Graeven, Süleyman Ergün, Sandra Verago, Nerbil Kilic, Marcus Stockschläder, Dieter K. Hossfeld

Blood (1997) 89 (6): 1870–1875.

https://doi.org/10.1182/blood.V89.6.1870

Published: 1997

NARROW

Impact of Clonal Heterogeneity in Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Subgroup Analysis of the GMMG HD6 Phase III Trial

Bortezomib in Combination with Ibrutinib/Rituximab Is a Highly Effective and Well Tolerated First - Line Treatment for Waldenström's Macroglobulinemia: Results of the Multicenter Phase II trial ( ECWM-2 ) of the European Consortium for Waldenström's Macroglobulinemia

Quality of Life in the Multicenter, Randomized, Phase 3 GMMG-HD6 Trial Applying Elotuzumab, Lenalidomide, Bortezomib and Dexaemethason in Patients with Newly-Diagnosed Multiple Myeloma

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)

Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma

Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma

Combining Information Regarding Chromosomal Aberrations t(4;14), Del(17p13) and the Copy Number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: Results From the HOVON-65/GMMG HD4 Trial

Front - Line Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves the Time to Treatment Failure and Overall Survival in Elderly Patients with Advanced Stage Follicular Lymphoma - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).

Vascular Endothelial Growth Factor, a Possible Paracrine Growth Factor in Human Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only